Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) Homo sapiens (Human) Multiplex ELISA

P3NP; N-Propeptide Of Type III Procollagen; Procollagen III Amino Terminal Propeptide

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA573Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-95 81
EDTA plasma(n=5) 78-103 81
heparin plasma(n=5) 90-104 101
sodium citrate plasma(n=5) 79-99 90

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-95% 83-99% 98-105% 81-93%
EDTA plasma(n=5) 84-97% 79-97% 80-99% 80-93%
heparin plasma(n=5) 81-102% 81-101% 82-94% 85-101%
sodium citrate plasma(n=5) 80-90% 87-96% 82-90% 81-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PIIINP) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Increment services

Citations

  • Characterization of the specific and sustained GH1 expression induced by rAAV2/1 in normal adult male ratsPubMed: 20204528
  • A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related FibrosisPubMed: 20532833
  • Comparison of Five Liver Fibrosis Indexes with Serum Levels of Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis PatientsIntechopen: 18785
  • Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial.Trials: 1745-6215
  • Aliskiren and Perindopril Reduce the Levels of Transforming Growth Factor-β in Patients With Non-Diabetic Kidney DiseaseNature: 201214
  • Raised circulating tenascin-C in rheumatoid arthritis.PubMed: 23193984
  • Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure.PubMed: 23067911
  • Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B.PubMed: 22734888
  • Effects of coffee consumption in chronic hepatitis C: a randomized controlled trialPubmed: 23238034
  • Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosisPubmed: 23922364
  • Prevalence, etiology and risk factors of pelvic organ prolapse in premenopausal primiparous womenSpringer: Source
  • Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver FibrosisScienceDirect: S0973688314000073
  • Retroperitoneale FibroseSpringer:Source
  • The status of the pelvic floor in young primiparous womenWiley:Source
  • Clinical significance of markers of collagen metabolism in rheumatic mitral valve diseasePubmed:24603967
  • Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in childrenPubmed:24768785
  • Fast food diet with CCl4 micro-dose induced hepatic-fibrosis-a novel animal modelPubmed:24884574
  • DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2Pubmed:24945829
  • Correlation of HBsAg titers with serum fibrotic maker in patients with chronic hepatitis B infection.Pubmed:24974647
  • Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry diseasePubmed:25073565
  • B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related diseasePubmed:25143523
  • Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with HypertensionPubMed: 25747153
  • The Multi-Biomarker Approach for Heart Failure in Patients with HypertensionPubMed: 25984599
  • The Relationship of the Degree of Hepatic Fibrosis with Hyaluronic Acid, Type 4 Collagen, and Procollagen Type 3 N-Terminal Peptide Levels in Patients with Chronic Viral HepatitisOpenview: 8A0B8C97D72C61741371F33508760B75
  • Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol dietdoi:10.1111
  • Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial populationPubmed:26776557
  • Procollagen markers in microdialysate can predict patient outcome after Achilles tendon rupturecontent:2
  • Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathypubmed:27516211
  • Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRRpubmed:28004175
  • Extracellular microRNA signature in chronic kidney disease.pubmed:28077372
  • Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathypubmed:27889753
  • Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscleand Liver Fibrosis in Mice.pubmed:27458976
  • 5-methoxytryptophan is a potential marker for post-myocardial infarction heart failure - apreliminary approach to clinical utility.pubmed:27526355
  • Urinary Type III Procollagen Is Associated With Chronic Allograft Dysfunction and Predicts Graft Survival.pubmed:28219585
  • Achilles tendon rupture healing is enhanced by intermittent pneumatic compression upregulating collagen type I synthesispubmed:28668970
  • Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Studypubmed:28054933
  • Profilin‑1 contributes to cardiac injury induced by advanced glycation end‑products in ratspubmed:28901418
  • Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellituspubmed:28685602
  • Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR10.1007/s00380-016-0930-y
  • Matrix Degradation in Human Immunodeficiency Virus Type 1–Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study10.1093/cid/cix231
  • 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.pubmed:28460256
  • Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.pubmed:29120858
  • Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in EldersPubmed:29602632
  • The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Studyarticle:10.1007
  • Circulating matrix metalloproteinases and procollagen propeptides in inguinal herniaPubmed:29484522
  • Assessment of myocardial fibrosis by late gadolinium enhancement imaging and biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation.Pubmed:29443354
  • Association between reverse electrical remodeling and cardiac fibrosis markers in patients with cardiac resynchronization therapyPubmed:29512624
  • N-терминальный пропептид проколлагена III типа в качестве возможного сывороточного маркера фиброза миокарда у больных сахарным диабетом 2 …:
  • Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic BlockadePubmed: 30239650
  • microRNA-29a inhibits cardiac fibrosis in Sprague-Dawley rats by downregulating the expression of DNMT3A.Pubmed: 30297596
  • Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study designDoi: 10.1016/j.cct.2018.10.012
  • Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related diseasePubmed: 30547825
  • Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung InjuryPubmed: 30521764
  • Direktor: Prof. Dr. med. Andreas Mügge
  • Low fibrosis biomarker levels predict cardiac resynchronization therapy responsePubmed: 30988339
  • Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotypePubmed: 30972180
  • Gum Acacia mitigates diclofenac nephrotoxicity by targeting monocyte chemoattractant protein-1, complement receptor-1 and pro-apoptotic pathwaysPubmed: 31042592
  • Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis IndexPubmed: 31468264
  • Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of FibrosisPubmed: 33224989
  • Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapyPubmed: 33069226
  • A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trialPubmed: 32578850
  • Ассоциации толщины эпикардиального жира и циркулирующих маркеров фиброза миокарда у пациентов с инфарктом миокарда
  • Association of Non©\Steroidal Anti©\Inflammatory Drugs with Kidney Health in Ambulatory Older Adults33305369
  • Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after?¡­33431713
  • Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial33614272
  • Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis34104667
  • A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes32578850
  • The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized …34684621
  • Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus34778465
  • Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy34296634
  • Simple Predictors for Cardiac Fibrosis in Patients with Type 2 Diabetes Mellitus: The Role of Circulating Biomarkers and Pulse Wave VelocityPubmed:35628969
  • Increase in Serum MMP-9 and TIMP-1 Concentrations during Alcohol Intoxication in Adolescents—A Preliminary StudyPubmed:35625637

Recommend products